Alnylam Pharma (ALNY) Tops Q1 EPS by 35c

Alnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($1.49), $0.35 better than the analyst estimate of ($1.84). Revenue for the quarter came in at $213.26 million versus the consensus estimate of $243.02 million.

For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.

You May Also Be Interested In

• BMO Capital Starts Alnylam Pharmaceuticals (ALNY) at Outperform
• John B. Sanfilippo & Son (JBSS) Misses Q4 EPS by 59c
• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance